Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1140582

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279389
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140584

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has provide information to patients on changes to the provision of medicines as a result of the serious shortage protocol; and if he will make a statement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279390
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279391 question first answered 26/07/2019 11:36:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131087 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140585

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions the Government has had with (a) patient groups and (b) professional bodies on the development of the serious shortage protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279391
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279390 question first answered 26/07/2019 11:36:13 answering member 4455 label Biography information for Seema Kennedy previous answer version 131085 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1137560

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sexually Transmitted Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the correlation between reductions to public health funding and increases in rates of syphilis and gonorrhoea.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274471
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We estimate that increases in rates of syphilis, gonorrhoea and chlamydia are due to a number of factors. These include increases in both the number of people attending sexual health services and the number of tests for sexually transmitted infections. Public Health England has advised that other factors include, better detection of infection and behavioural changes such as an increase in partner numbers and condomless sex, as well as, for some men who have sex with men, ‘chemsex’ and group sex facilitated by geosocial networking applications.</p><p> </p><p>Local authorities will receive £3.1 billion in 2019/20, ring-fenced exclusively for use on public health, including sexual health. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for sexual health services taking account of their statutory duties.</p><p> </p><p>Local authorities are required by regulations to provide comprehensive open access sexual health services, including provision for sexually transmitted infection testing and treatment and contraception.</p><p> </p><p>The latest statistics show that more people are now accessing sexual health services. Attendances have increased by 7% between 2017 and 2018 (from 3,337,677 to 3,561,548). This continues the trend of increases in attendances seen over the past five years. To help manage the overall increase in demand, local authorities are increasingly commissioning online services to manage lower risk and asymptomatic patients. These services have the potential to reach groups not currently engaged with clinic services.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:19:43 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1137563

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Preventive Medicine: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Green Paper on Prevention will include and assessment of the level of funding required to implement the contents of that Green Paper.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274472
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We are considering a number of policy options for the Prevention Green Paper and will be mindful of the level of funding that may be required for their implementation.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:32:12 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1137564

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genito-urinary Medicine and HIV Infection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Prevention Green Paper will include (a) commitments on additional resources to tackle HIV and (b) targets to improve sexual health.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274473
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We are considering a range of policy options for the Green Paper and will be mindful of HIV and sexual health.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:32:41 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1128556

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when his Department plans to publish data on the uptake of influenza vaccinations by social care workers in 2018-19.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	257680
	answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>There is no nationally agreed data set or data collection for recording the immunisation of social care workers.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 05/06/2019 15:16:16 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1121453

	registered interest
	date	11/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution on 26 March 2019 to Question 910028 on Antimicrobial Resistance: Vaccines, what steps his Department is taking to stimulate research and development into vaccines, including for tuberculosis, as an alternative to antibiotics.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	244039
	answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>The United Kingdom national action plan on antimicrobial resistance (AMR), published on 24 January 2019, contains the commitment to continue to support research into new and alternative treatments, vaccines and diagnostic tests.</p><p>The Government has invested over £350 million in AMR research and development since 2014, including research funding calls with vaccination in scope, most recently the £32 million capital funding call lead by the National Institute for Health Research (NIHR), and the Small Business Research Initiative competition which announced its awards in January 2019. We would expect to consider the role of vaccines for AMR in future programmatic funding.</p><p>The UK supports the development of vaccines through UK Aid programmes such as the Global AMR Innovation Fund (GAMRIF) and the UK Vaccine Network. GAMRIF is a £50 million fund to support innovative research and development for AMR, for the benefit of people in low- and middle-income countries, and invests £30 million into preventative measures in human and animal health, including vaccines for AMR not including tuberculosis (TB). The fund includes a £1 million work package with the Bacterial Vaccinology Network which supports early stage research and development around the world to drive the development and uptake of vaccines for AMR in humans and animals.</p><p>The UK supports TB vaccine research through the Medical Research Council (MRC), with support to the European and Developing Countries Clinical Trials Partnership, and through the Joint Global Health Clinical Trials programme represented by the Department for International Development (DFID), MRC, NIHR and Wellcome. DFID’s Agriculture research team is supporting work on bovine TB vaccine development in partnership with the Bill and Melinda Gates Foundation.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 244040 question first answered 24/04/2019 08:08:02 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1121454

	registered interest
	date	11/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution on 26 March 2019 to Question 910028 on Antimicrobial Resistance: Vaccines, what funding he plans to make to stimulate research and development into vaccines as an alternative to antibiotics.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	244040
	answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>The United Kingdom national action plan on antimicrobial resistance (AMR), published on 24 January 2019, contains the commitment to continue to support research into new and alternative treatments, vaccines and diagnostic tests.</p><p>The Government has invested over £350 million in AMR research and development since 2014, including research funding calls with vaccination in scope, most recently the £32 million capital funding call lead by the National Institute for Health Research (NIHR), and the Small Business Research Initiative competition which announced its awards in January 2019. We would expect to consider the role of vaccines for AMR in future programmatic funding.</p><p>The UK supports the development of vaccines through UK Aid programmes such as the Global AMR Innovation Fund (GAMRIF) and the UK Vaccine Network. GAMRIF is a £50 million fund to support innovative research and development for AMR, for the benefit of people in low- and middle-income countries, and invests £30 million into preventative measures in human and animal health, including vaccines for AMR not including tuberculosis (TB). The fund includes a £1 million work package with the Bacterial Vaccinology Network which supports early stage research and development around the world to drive the development and uptake of vaccines for AMR in humans and animals.</p><p>The UK supports TB vaccine research through the Medical Research Council (MRC), with support to the European and Developing Countries Clinical Trials Partnership, and through the Joint Global Health Clinical Trials programme represented by the Department for International Development (DFID), MRC, NIHR and Wellcome. DFID’s Agriculture research team is supporting work on bovine TB vaccine development in partnership with the Bill and Melinda Gates Foundation.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 244039 question first answered 24/04/2019 08:08:03 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb